Recently, iPSCs have attracted attention as a new source of cells for regenerative therapies. Although the initial method for generating iPSCs relied on dermal fibroblasts obtained by invasive biopsy and retroviral genomic insertion of transgenes, there have been many efforts to avoid these disadvantages. Human peripheral T cells are a unique cell source for generating iPSCs. iPSCs derived from T cells contain rearrangements of the T cell receptor (TCR) genes and are a source of antigen-specific T cells. Additionally, T cell receptor rearrangement in the genome has the potential to label individual cell lines and distinguish between transplanted and donor cells. For safe clinical application of iPSCs, it is important to minimize the risk of exposing newly generated iPSCs to harmful agents. Although fetal bovine serum and feeder cells have been essential for pluripotent stem cell culture, it is preferable to remove them from the culture system to reduce the risk of unpredictable pathogenicity. To address this, we have established a protocol for generating iPSCs from human peripheral T cells using Sendai virus to reduce the risk of exposing iPSCs to undefined pathogens. Although handling Sendai virus requires equipment with the appropriate biosafety level, Sendai virus infects activated T cells without genome insertion, yet with high efficiency. In this protocol, we demonstrate the generation of iPSCs from human peripheral T cells in feeder-free conditions using a combination of activated T cell culture and Sendai virus.
Introduction
iPSCs have attracted considerable attention as a groundbreaking source of cells for regenerative medicine [1] [2] [3] . To date, diverse methods for generating iPSCs have been reported 4, 5 . Among these, iPSCs generated from human T cells have been of particular interest because of the less-invasive method of cell sampling [6] [7] [8] . Additionally, iPSCs derived from T cells contain rearrangements of the T cell receptor (TCR) gene and are thus a source of antigen-specific T cells 9, 10 . Therefore, generating T cell derived iPSCs safely is useful for progressing regenerative medicine.
This method is based on the concept of reducing the risk of unpredictable pathogenicity. For safe clinical application of iPSCs it is important to reduce the risk of exposure to pathogens 11 . Previously in many culture systems of pluripotent stem cells, fetal bovine serum and feeder cells have been used as essential reagents 12 . However, removal of both these reagents from the culture system is preferable for iPSC generation to reduce the risk of unpredictable pathogenicity.
Additionally, this method has the advantage of avoiding invasive cell sampling from patients and laborious preparation of feeder cells. Because T cell derived iPSCs have already been used successfully in disease research 13, 14 , this method is also applicable and useful for generating disease-specific iPSCs from patients.
Among T cell reprogramming methods, using the Sendai virus (SeV) vector as a gene vehicle is a method that can generate iPSCs with high efficiency 7, 16 . Additionally, because SeV is a single-stranded RNA virus and does not need a DNA phase for replication, its use in iPSC generation avoids breaking the host genome [17] [18] [19] . Therefore, we have established protocols for generating iPSCs from human peripheral T cells in serum-free and feeder-free conditions using a combination of matrigel, mTeSR medium, and SeV vectors. 10 . Prepare an anti-human CD3 antibody solution at a concentration of 10 µg/ml in D-PBS(-). Add the anti-human CD3 antibody solution to a 6-well plate, soak the surface of each well, and incubate the dish at 37 °C in a 5% CO 2 incubator for at least 30 min. 11. Remove the anti-human CD3 antibody solution from each well and wash once with D-PBS(-) just prior to seeding the cells. 12. Seed mononuclear cells that were prepared in Step 1.9 at a density of 2.5 × 10 5 cells/cm 2 on the anti-human CD3 antibody-coated 6-well plates in KBM502 medium. Incubate at 37 °C in a 5%-CO 2 incubator for 3-7 days without medium change until the T cells reach confluency. T cells in this period are both suspended and adhering cells. 
Protocol

Prepare Activated Human T Cells
Infect Human T Cells with SeV Vectors
Remove SeV Vectors from Human T Cells
1. 24 hr after infection, collect the infected cells with a pipette. If there are adhering cells, they can easily be detached pipetting them repeatedly up and down. Transfer them to a 15-ml conical tube, and centrifuge at 200 × g for 5 min at RT. 2. Remove the supernatant containing the SeV vectors, and add 2 ml fresh KBM502 medium. Replate cells in each of the wells. Incubate at 37°C in a 5%-CO 2 incubator for an additional 24 hr.
Reseed Cells on a Matrigel Layer
1. Prepare basement membrane matrix solution by thawing matrix gel (please see the Materials List for the specific brand used in this study) at 4 °C and dissolving 0.2 ml in 10 ml of DMEM/F12 medium. Note: Matrix gel (please see the Materials List for the specific brand used in this study) needs to thaw O/N at 4 °C to be completely thawed.
Keep it on ice until just before use. 2. Plate 5 ml basement membrane matrix solution per dish into 100-mm dishes and leave at RT for at least 30 min before seeding cells. At least two 100-mm dishes are needed for one experiment. 3. Collect SeV-infected cells by pipetting, transfer them to a 15-ml conical tube, and centrifuge at 200 × g for 5 min at RT. 4. Remove the supernatant and add 1 ml fresh KBM502 medium. Count the number of cells using a hemocytometer, remove the basement membrane matrix solution from 100-mm dishes prepared in Step 4.2 and plate 1 × 10 5 and 1 × 10 6 cells (in 10 ml fresh mTeSR medium) on a 100-mm basement membrane matrix-coated dishes. Finally, use the plate in which colonies are easily picked. 5. Incubate the dish at 37 °C in a 5%-CO 2 incubator O/N. 6. Change the medium to 10 ml flesh mTeSR medium every other day.
Note: Approximately 20-30 days after infection, colonies that closely resemble embryonic stem cells (ESCs) will appear.
Expand T Cell-derived iPSCs
1. Change the mTeSR medium every 1-2 days. 2. When the colonies become confluent every 5-7 days, passage the cells using dissociation solution for human iPSCs and human ESCs according to the manufacturer's instructions.
Representative Results
Using this protocol, users are able to generate iPSCs from human peripheral T cells stably. iPSC generation from T cells with SeV and matrigel showed approximately 0.002% -0.005% of efficiency of cell reprogramming in between several donor cases and SeV were not detected after several passages 16 . Figure 1A shows a schematic of the protocol for generating T cell-derived iPSCs in feeder-free conditions using matrigel and mTeSR medium. Around 20-30 days after infection with SeV, iPSC colonies are recognized by their ESC colony-like morphology ( Figure  1B) . Immunofluorescence staining revealed expression of typical pluripotent cell markers (NANOG, OCT3/4, SSEA4, TRA-1-60, and TRA-1-81) in T cell-derived iPSCs generated under feeder-free conditions ( Figure 1C) . 
Discussion
We describe a protocol for generating iPSCs from human peripheral T cells in serum-free and feeder-free conditions using a combination of matrigel, mTeSR medium, and SeV vectors. For clinical applications of iPSCs, it is important to have a protocol for stably generating iPSCs and a less-invasive method for cell sampling. Although generating iPSCs with the combination of matrigel and mTeSR medium showed lower reprogramming efficiency than that with knockout serum replacement (KSR) medium and feeder-cells, this combination achieves stable generation of iPSCs from donors 16 . Stable iPSC generation and less-invasive cell sampling has the advantage of being able to increase the number of donors for iPSC generation.
SeV vectors, a minus-strand RNA virus, is not integrated into the host genome. Therefore the risks of tumorigenesis can be avoided at the step of reprogramming factor induction [20] [21] [22] [23] [24] . Additionally, the feeder-free conditions, which use a combination of defined culture medium and matrigel instead of a feeder layer, make it possible to minimize the potential risks of exposure to unknown exogenous factors. The fusion of these techniques provides a less invasive and safer iPSC technology for regenerative medicine 16 . Important steps in this protocol are the step of activating human T cells (Step 1) and infecting them with SeV vectors (Step 2). When no ESClike colony is obtained in the culture dish at an optimal time after SeV infection, the following should be considered. First, the confluency of the mononuclear cells before T cell activation may not be appropriate because optimal activation of T cells is critical for SeV infection 25, 26 . Too high a density of mononuclear cells leads to cell death, interfering with the proper activation of T cells. Too low a density of mononuclear cells also disturbs the proper activation and proliferation of T cells. Therefore, the confluency of mononuclear cells should be checked and adjusted accordingly. Second, the dosage of SeV vectors may not be sufficient. The induction efficiency of iPSC colonies depends on the dosage of the virus 6 . If no ESC-like colony is observed after SeV infection, the option of increasing the virus dosage up to an MOI of 15-20 should be considered. If signs of iPSC colony differentiation are observed, the frequency at which medium is changed may be increased up to every other day, or to every day when colonies are larger.
The limitation in this protocol consists of this method not being virus free. Although SeV for cell reprogramming is commercially available with ease, users need to prepare equipment according to the appropriate biosafety level. As another method for generating integration-free iPSCs, episomal vectors have been used until now [27] [28] [29] . Although episomal vectors can be used with equipment with a lower level of biosafety, episomal vectors might insert into the host genome at extremely low rates. Therefore, additional checks are required to confirm the disappearance of transgenes, as when using SeV.
There is another limitation in that this technique is not absolutely free from animal-derived products. Some substrates, such as matrigel, anti-CD3 mAb, dissociation solution and SeV solution are derived from animal products and are therefore associated with a risk of transferring xenogeneic pathogens. However, the reduction of animal-derived substrates in the culture system is meaningful for the clinical application of iPSC technology due to the lower risk.
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